Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's D&A?
- Aclaris Therapeutics (ACRS) reported D&A of $107K in Q2 2026.
- How has Aclaris Therapeutics's D&A changed year-over-year?
- Aclaris Therapeutics's D&A decreased by 6.1% year-over-year, from $114K to $107K.
- What is the long-term trend for Aclaris Therapeutics's D&A?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's D&A has grown at a -16.3% compound annual growth rate (CAGR), from $923K to $454K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Aclaris Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude